Wall St. extends run of record highs; services data upbeat

Wells Fargo (WFC) PT Raised to $57 at UBS on 3Q17 U.S. Banking Preview; 'Economic Growth Conditions to Drive Bank Stocks'

UBS raised its price target on Wells Fargo (NYSE: WFC) to $57.00 (from $56.00) while maintaining a Neutral rating, following a third quarter 2017 U.S. Banking preview.

Analyst Saul Martinez notes a positive outlook following the third quarter 2017 U.S. Banking preview, as the... More

Netflix (NFLX) PT Raised to $225 at Rosenblatt Following Announced Price Increase

Rosenblatt raised its price target on Netflix (NASDAQ: NFLX) to $225.00 (from $200.00) while maintaining a Buy rating following the company's announcement that it will be raising prices in the US. The company will raise prices by 10% on its most popular service, 17% on its... More

Netflix (NFLX) PT Raised to $180 at Jefferies Following Announced Priceing Move

Jefferies raised its price target on Netflix (NASDAQ: NFLX) to $180.00 (from $165.00) while maintaining a Hold rating. The company plans to raise the price of its standard / premium plans by $1 / $2 per mo., respectively. Press reports indicate that the new prices will take place immediately for new US... More

Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley

Morgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.

Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'

Barclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while maintaining a Equalweight rating, following an update on the U.S. Specialty Pharmaceutical industry, as the FDA recently approved a generic Copaxone formulation.

Analyst Douglas Tsao notes a... More

Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform

Cowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.

With this approval the... More